anonymous
Guest
anonymous
Guest
MULTI YEAR LOWS. THIS COMPANY HAS UNDERPERFORMED AGAINST ALL CATEGORIES. THIS EXECUTIVE LEADERSHIP HAS FAILED MISERABLY!
Funny you ask: https://www.statnews.com/2017/12/12/worst-biopharma-ceos-2017/Has anyone seen a list of the worst performing biopharma industry stocks in 2017? I'm wondering if Shire is on the list.
Hopeflly this new low will trigger some big buying, especially ahead of next week’s earnings call. If not, many of us who have options are going to get screwed over royally. You are also screwed if you participated in the ESPP last year.Shire has a new low! 127.42 at 1:06 pm
Hopefully only a tiny percentage of your portfolio is tied up in Shire stock.There goes my retirement.
just think how bad this stock slide is hitting Flemming's own pocket
at least we know he is hurting himself as he hurts all of us
If not hitting his wallet, he should still take a hit with the board and with the analysts on next week’s earnings call. Who knows, he might get replaced with a modest, down-to-earth CEO who inspires the ranks and vacations at Disney World.Are you kidding me ??? That’s right up there with the most idiotic thing that I have heard- the stock loss is just on paper to him, and likely a tax write off. It’s not affecting him anywhere near how it’s impacting those of us in the trenches.
...and a few weeks later we are sitting at only $133. Cut your losses and buy AbbVie which is rockin it and pays a better dividend.At least it’s back up today to $132 ahead of this week’s earnings call. Still no where where it needs to be for us to make any money but at $132 at least we are on track to mitigate losses. Hopefully the earnings call will give a further boost.